# Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism

> **NCT05654701** · — · APPROVED_FOR_MARKETING · sponsor: **Ascendis Pharma Bone Diseases A/S**

## Conditions studied

- Hypoparathyroidism

## Interventions

- **DRUG:** Palopegteriparatide (TransCon PTH)

## Key facts

- **NCT ID:** NCT05654701
- **Lead sponsor:** Ascendis Pharma Bone Diseases A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05654701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05654701, "Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05654701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*